无症状性颈动脉狭窄最佳管理的近期进展与争议问题
本文更新了2021年专家综述与立场声明,系统检索截至2023年8月1日的文献,聚焦无症状性颈动脉狭窄(AsxCS)诊断与管理进展。所有AsxCS患者均应接受最佳药物治疗(BMT),部分高危亚组可考虑颈动脉血运重建;AsxCS与认知功能障碍的关联缺乏可靠证据。
要点
- 所有AsxCS患者均须接受BMT,无论是否最终接受CEA、CAS或TCAR。
- 尽管接受BMT仍卒中高危的特定亚组可考虑颈动脉血运重建。
- AsxCS与认知功能障碍关联的可靠证据缺乏,未来需进一步研究。
核心结论
- AsxCS最佳管理应包括所有个体接受BMT,部分无症状患者亚组接受预防性颈动脉血运重建(CEA、CAS或TCAR),并考虑个体需求与偏好、临床与影像特征、社会文化因素及可用的卒中风险预测模型。
- 未来研究应探讨AsxCS与认知功能的关联以及颈动脉血运重建在认知功能障碍进展或逆转中的作用。
研究设计与样本
- 本文为2021年专家综述与立场声明的更新,采用系统文献综述方法。
- 检索截至2023年8月1日,数据库为PubMed/PubMed Central、EMBASE和Scopus。
- 检索关键词组合包括「无症状性颈动脉狭窄」「颈动脉内膜切除术」(CEA)、「颈动脉支架置入术」(CAS)和「经颈动脉血运重建术」(TCAR)。
主要发现
- BMT对所有AsxCS患者均必不可少,无论其最终是否接受CEA、CAS或TCAR。
- 尽管接受BMT仍卒中高危的特定患者亚组应考虑颈动脉血运重建,包括重度(≥80%)AsxCS、经颅多普勒检测到的微栓子、双功能超声显示斑块回声透亮、脑CT或MR血管成像扫描上的静息梗死、脑血管储备下降、近腔低回声区面积增大、AsxCS进展、颈动脉斑块溃疡和斑块内出血。
- AsxCS患者的治疗应个体化,考虑个体患者偏好与需求、临床与影像特征以及文化、民族和社会因素。
- 支持或反驳AsxCS与认知功能障碍关联的可靠证据缺乏。
关键数值与推荐
- 重度AsxCS定义为狭窄程度≥80%。
- 高危亚组特征包括经颅多普勒检测到的微栓子、双功能超声显示斑块回声透亮、脑CT或MR血管成像扫描上的静息梗死、脑血管储备下降、近腔低回声区面积增大、AsxCS进展、颈动脉斑块溃疡和斑块内出血。
临床怎么用
- 所有AsxCS患者均应接受BMT。
- 尽管接受BMT仍卒中高危的特定亚组可考虑颈动脉血运重建(CEA、CAS或TCAR),并应个体化考虑患者偏好、临床与影像特征及社会文化因素。
局限性
- 支持或反驳AsxCS与认知功能障碍关联的可靠证据缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The optimal management of patients with asymptomatic carotid stenosis (AsxCS) is enduringly controversial. We updated our 2021 Expert Review and Position Statement, focusing on recent advances in the diagnosis and management of patients with AsxCS. METHODS: A systematic review of the literature was performed up to August 1, 2023, using PubMed/PubMed Central, EMBASE and Scopus. The following keywords were used in various combinations: "asymptomatic carotid stenosis," "carotid endarterectomy" (CEA), "carotid artery stenting" (CAS), and "transcarotid artery revascularization" (TCAR). Areas covered included (i) improvements in best medical treatment (BMT) for patients with AsxCS and declining stroke risk, (ii) technological advances in surgical/endovascular skills/techniques and outcomes, (iii) risk factors, clinical/imaging characteristics and risk prediction models for the identification of high-risk AsxCS patient subgroups, and (iv) the association between cognitive dysfunction and AsxCS. RESULTS: BMT is essential for all patients with AsxCS, regardless of whether they will eventually be offered CEA, CAS, or TCAR. Specific patient subgroups at high risk for stroke despite BMT should be considered for a carotid revascularization procedure. These patients include those with severe (≥80%) AsxCS, transcranial Doppler-detected microemboli, plaque echolucency on Duplex ultrasound examination, silent infarcts on brain computed tomography or magnetic resonance angiography scans, decreased cerebrovascular reserve, increased size of juxtaluminal hypoechoic area, AsxCS progression, carotid plaque ulceration, and intraplaque hemorrhage. Treatment of patients with AsxCS should be individualized, taking into consideration individual patient preferences and needs, clinical and imaging characteristics, and cultural, ethnic, and social factors. Solid evidence supporting or refuting an association between AsxCS and cognitive dysfunction is lacking. CONCLUSIONS: The optimal management of patients with AsxCS should include BMT for all individuals and a prophylactic carotid revascularization procedure (CEA, CAS, or TCAR) for some asymptomatic patient subgroups, additionally taking into consideration individual patient needs and preference, clinical and imaging characteristics, social and cultural factors, and the available stroke risk prediction models. Future studies should investigate the association between AsxCS with cognitive function and the role of carotid revascularization procedures in the progression or reversal of cognitive dysfunction.
引用
- Paraskevas KI, Brown MM, Lal BK, et al. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis. J Vasc Surg. 2023. PMID: 37939746. doi:10.1016/j.jvs.2023.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。